|
Monday 15th October |
| |
|
|
17:00-
19:00 |
|
Registration opens
and drinks reception
|
|
|
|
|
|
Tuesday 16th October |
| |
|
|
08:00-
09:00 |
|
Registration continues
|
|
|
|
|
|
09:00 |
|
Chairpersons' Opening Address
Rowan Stringer (Novartis) and Johanna Haglund (MetaSafe – an Admescope company) |
|
09:15 |
|
Session 1: Strategic
collaborations: Pan European Industrial – Academic Partnerships
Chair: Pawel Baranczewski, Uppsala University (pawel.baranczewski@farmaci.uu.se)
Speakers:
- What have industrial/academic partnerships ever done for us?
Steve Hood, GSK
- Quantitative Systems Pharmacology is alive and well in the UK
James Yates, AstraZeneca
- Academic–Industrial Partnerships in Drug Discovery-Opportunity or Foe for Academic Research. Comments from Academic Point of View
Pawel Baranczewski, UDOPP, Uppsala University
|
|
10:45 |
|
Coffee, Posters, Trade
Exhibition |
|
11:15 |
|
Session 2: Strategic
approaches to tissue quantification
Chair: Johan Bylund, Medivir
(johan.bylund@medivir.com)
Speakers:
- To measure or not to measure? Tactics of tissue exposure assessment in drug research
Markus Fridén, AstraZeneca
- Determination of total tumor concentrations in xenograft models; experiences from Merck oncology projects
Carl Petersson, Merck KGA
- Bioanalytical aspects of tissue quantification, experiences from a Medivir oncology project
Rodrigo Palma Villar, Medivir
|
|
12:45 |
|
Lunch, Posters, Trade
Exhibition |
|
13:30 |
|
Session 3: Strategies
for PKPD Modelling in Drug Discovery and Development
Chairs: Maria Kjellsson, Uppsala University
(Maria.Kjellsson@farmbio.uu.se)
Speakers:
- Preclinical PK/PD modelling to support First-in-Man trial in oncology
Sheila Annie Peters, Merck KGaA
- Translational pharmacokinetic-pharmacodynamic modelling predicts human exposure-target engagement
Rasmus J. Löfmark, AstraZeneca
- - Using modelling & simulation throughout clinical drug development
Hanna Silber Baumann, F. Hoffmann-La Roche
|
|
15:00 |
|
Coffee, Posters, Trade
Exhibition |
|
15:30 |
|
Session 4: Student
Poster Blitz/ Rosenön award
Chairs: Hugh Walton, Astex (Hugh.Walton@astx.com) and Johanna Haglund, MetaSafe – an Admescope company
(johanna.haglund@metasafe.se) |
|
16:30 |
|
Candlelight Keynote Speaker
Chair: Rasmus Jansson Löfmark, AstraZeneca,
(Rasmus.Jansson.Lofmark@astrazeneca.com)
Speaker: Magnus Ingelman-Sundberg, Karolinska Institute
Title: Drugs, genes and precision medicine, a tour from RFLP to NGS |
17:30 -
19:30 |
|
Poster Session
Drinks Reception, Trade Exhibition
Chair: Hugh Walton, Astex (Hugh.Walton@astx.com) |
|
19:30 |
|
Dinner (Own
Arrangements) |
|
|
|
|
|
Wednesday 17th
October |
|
|
|
|
|
08:45 |
|
Session 5: New
Technologies in DMPK
Chair: Mark Seymour, Covance
(Mark.Seymour@covance.com)
Speakers:
- New Horizons in DMPK: The Next Wave of Automation
Scott Summerfield, GSK
- The Application of Ion Mobility Mass Spectrometry in DMPK Workflows
Richard Clayton, Covance
- Evaluation of transporter activity in stem cell derived renal models for drug clearance studies
Katarina Breitholtz, AstraZeneca
|
|
10:15 |
|
Coffee, Posters, Trade
Exhibition |
|
10:45 |
|
Session 6: New
Modalities – Part 1
Chair: Lars Weidolf, AstraZeneca
(Lars.Weidolf@astrazeneca.com)
Speakers:
- Chemical Analysis and Physicochemical Characterization of Peptides - a Chemistry Perspective
Tomas Leek, AstraZeneca
- ADME Characteristics of Semaglutide
Mette Lund Pedersen, NovoNordisk
- 14C-Labeling and Analysis Technologies to Enable Biologicals Drug Development
Wouter Vaes, TNO
- Highlights from the 1st workshop of the Peptide ADME Discussion Group
Jesper Kammersgaard Christensen, NovoNordisk
|
12:30-
13:30 |
|
Lunch, Posters, Trade
Exhibition
|
|
13:30 |
|
Session 8: New
Modalities – Part 2
Chair: Joanne Goodman, MedImmune
(goodmanj@MedImmune.com)
Speakers:
- Bioanalytical Strategy for Locked Nucleic Acids (LNA) Therapeutics: Lessons Learned
Enric Bertran, F. Hoffmann-La
Roche
- Bioanalysis and Biodistribution of Dendrimer Nanoparticles
Eric Gangl, AstraZeneca
- Discussion and Reflection Points from the EBF Focus Workshop on New Modalities: Science and Regulations Joining Hands
Philip Timmerman (on behalf of the European Bioanalytical Forum (EBF))
|
|
15:00 |
|
Coffee, Posters, Trade
Exhibition |
15:30 -
17:00 |
|
Session 8: Free Communicationss
Chair: Graeme Scarfe, AstraZeneca (Graeme.Scarfe@astrazeneca.com)
Speakers:
- Target-mediated drug disposition for small molecules: an overlooked area?
Robert van Waterschoot, F. Hoffmann-La
Roche
- Application of in vitro parameters to predict non-linear absorption
Katie Haughan, AstraZeneca
- The rise of Deuterated Drugs
Ray Cooke, Pharmaron
- Development of a novel method to rapidly characterise uptake transporter activity in human hepatocytes in vitro: Applications and learnings
Oliver Light, UCB
|
17:30 -
19:00 |
|
Session 9: Debate:
Lipinski Rules are no longer relevant – Future drugs will need to be
>5 kDa if they are to become “profitable” medicines
Ringmaster: Steve Hood, GSK
(steve.r.hood@gsk.com)
- Proposing -
Kevin Brady (UCB) and Ben Krippendorff (F.
Hoffmann-La Roche)
- Against -
Dennis Smith (DMDG Fellow) and Barry Jones (AstraZeneca)
|
|
|
|
|
19:30-
00:00 |
|
Drinks Reception,
Conference Dinner
|
|
|
|
|
|
Thursday 18th October |
|
|
|
|
|
09:00 |
|
Session 10: First In
Human dose – regulatory and pharmacokinetic-pharmacodynamic
considerations
Chair: Rasmus J. Löfmark, AstraZeneca (Rasmus.Jansson.Lofmark@astrazeneca.com)
Confirmed speakers:
- The new EMA First In Human guideline
René Bouw, MPA
- IQ MABEL: First In Human MABEL approach and Survey Results
Sherri Dudal, UCB
- Integrated PKPD approach for the first-in-human dose selection of novel co-stimulatory cancer immunotherapies
Wouter Driessen, F. Hoffmann-La Roche
|
|
10:30 |
|
Coffee, Posters, Trade
Exhibition |
|
11:00 |
|
Session 11: The
Application of DDI and PBPK in Regulatory Environment
Chair: Anna Nordmark, MPA
(Anna.Nordmark@mpa.se)
Confirmed speakers:
- The use of Physiologically Based Pharmacokinetic Models for Regulatory Claims within EMA
Anna Nordmark, MPA
- Physiologically based pharmacokinetic modelling current capabilities, case studies, and future opportunities:
A Consortium Perspective
Venkatesh Pilla Reddy, AstraZeneca
- Comparison Between the US FDA, EMA and Japan PMDA In Vitro DDI Guidances: Are we Closer to Harmonization?
Brian Ogilvie, Sekisui XenoTech
|
|
|
|
|
|
12:45 |
|
Closing Remarks |
13:00-
14:00 |
|
Lunch and Delegates
Depart
|
|
Click here to download a PDF version of the programme
|
|
In partnership with:
Sponsored by:
 
 
 
|